Colfax Announces Pricing of 6.000% Senior Notes Due 2024 and 6.375% Senior Notes Due 2026
January 31, 2019 at 05:22 pm
Share
??Colfax Corporation announced the pricing of $600 million aggregate principal amount of 6.000% Senior Notes due 2024 and $400 million aggregate principal amount of 6.375% Senior Notes due 2026 (the Notes) issued by CFX Escrow Corporation. Colfax intends to use the net proceeds from the offering to finance a portion of the purchase price for the previously-announced acquisition of DJO Global Inc. Upon the closing of the acquisition, the Notes will become obligations of Colfax and will be guaranteed (the Guarantees) by certain of Colfax’s domestic subsidiaries (including DJO and certain of its subsidiaries). Colfax does not intend to assume any obligations under the Notes until the closing of the acquisition of DJO. Prior thereto, the Notes will be the sole obligation of CFX Escrow Corporation. The offering is expected to close on February 5, 2019, subject to customary closing conditions. The Notes and the related Guarantees have not been, and will not be, registered under the Securities Act of 1933, as amended (the Securities Act), or the securities laws of any other jurisdiction. As a result, the Notes and the related Guarantees may not be offered or sold within the United States to or for the account or benefit of any U.S. person unless the offer or sale would qualify for a registration exemption under the Securities Act and applicable state securities laws. Accordingly, the Notes and the related Guarantees are being offered only to a limited number of U.S. investors that CFX Escrow Corporation and Colfax reasonably believe to be qualified institutional buyers in accordance with Rule 144A under the Securities Act and to certain persons outside the United States in accordance with Regulation S under the Securities Act.
Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment develops, manufactures, and distributes rigid bracing products, orthopedic soft goods, vascular systems and compression garments, and hot and cold therapy products and offers recovery sciences products in the clinical rehabilitation and sports medicine markets, such as bone growth stimulators and electrical stimulators used for pain management. The Reconstructive segment develops, manufactures, and markets a variety of knee, hip, shoulder, elbow, foot, ankle, and finger implant products and surgical productivity tools. It also provides Novastep, a minimally invasive surgery (MIS) foot and ankle solutions.